EGFR and non-small cell lung carcinoma: Several oral targeted therapies directed at the tyrosine kinase inhibitor (TKI) domain of the EGFR gene have demonstrated superior efficacy in comparison with cytotoxic chemotherapy and these TKIs have transformed the standard of care for the treatment of advanced cEGFRm NSCLC.